Claims for Patent: 9,359,443
✉ Email this page to a colleague
Summary for Patent: 9,359,443
Title: | Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases |
Abstract: | Disclosed are compositions and methods comprising combinations of anti-CD74 and anti-CD20 antibodies or antigen-binding fragments thereof. The antibody combination may also be used with a therapeutic agent that is attached to antibody or fragment thereof or separately administered. The therapeutic agent may be an immunomodulator, a cytokine, a toxin or other known therapeutic agent. Preferably, the anti-CD74 and anti-CD20 antibody or fragment are part of a DNL complex. More preferably, combination therapy with the anti-CD74 and anti-CD20 antibody or fragment is more effective than either antibody alone, or the combination of unconjugated antibodies. Administration of combination induces apoptosis of target cells in diseases in which CD74 is overexpressed, such as solid tumors, B-cell lymphomas or leukemias, autoimmune disease, immune dysfunction disease or diabetes. Preferably, the target cells are B cells. |
Inventor(s): | Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), Rossi; Edmund A. (Woodland Park, NJ) |
Assignee: | IBC Pharmaceuticals, Inc. (Morris Plains, NJ) |
Application Number: | 14/520,596 |
Patent Claims: | 1. A method of killing human B cells comprising: a) obtaining a dock-and-lock (DNL) construct that comprises (i) at least one anti-CD74 antibody or antigen-binding fragment
thereof and (ii) at least one anti-CD20 antibody or antigen-binding fragment thereof, wherein the antibodies or fragments thereof bind to human CD20 or CD74, wherein the DNL construct is a hexavalent DNL construct comprising an IgG moiety and four Fab
moieties; and b) exposing human B cells to the DNL construct.
2. The method of claim 1, wherein the anti-CD20 antibody is rituximab or hA20. 3. The method of claim 1, wherein the anti-CD74 antibody is hLL1. 4. The method of claim 1, wherein the anti-CD20 and anti-CD74 antibodies are chimeric, humanized or human. |
Details for Patent 9,359,443
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2025-04-06 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2025-04-06 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2025-04-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.